

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended): A method for softening expression lines on a face and/or forehead in need thereof, comprising topically applying to one or more zones of the face or forehead marked with expression lines a composition comprising a physiologically acceptable medium, and 0.1% to 10% by weight of adenosine with respect to the total composition weight, in an amount [[of]] effective to provide a relaxing effect on skin associated with the expression lines, thereby softening the expression lines.

2-3. (Canceled).

4. (Previously Presented): The method according to claim 1, wherein the composition comprises 0.1% to 1% by weight of adenosine with respect to the total composition weight.

5-9. (Canceled).

10. (Previously Presented): The method according to Claim 1, comprising topically applying to the skin an amount of said composition effective to provide a relaxing effect on contractile fibroblasts associated with the expression lines, thereby softening the expression lines.

11-12. (Canceled).

13. (Previously Presented): The method according to claim 10, wherein the composition comprises 0.1% to 1% by weight of adenosine with respect to the total composition weight.

14-18. (Canceled).

19. (Currently Amended): The method of Claim 1, wherein said composition further comprises at least one adenosine compound selected from the group consisting of an agonist of an adenosine receptor, a compound which increases intra- or extra-cellular adenosine levels, 2'-deoxyadenosine, 2',3'-isopropoylidene adenosine, toyocamycin, 1-methyladenosine, N-6-methyladenosine, adenosine N-oxide, 6-methylmercaptapurine riboside, 6-chloropurine riboside, 5'-adenosine monophosphate, 5'-adenosine diphosphate, 5'-adenosine triphosphate, phenylisopropyl adenosine, 1-methylisoguanosine, N⁶-cyclohexyl adenosine, N⁶-cyclopentyl adenosine, 2-chloro-N-6-cyclopentyladenosine, 2-chloroadenosine, N⁶-phenyladenosine, 2-phenylaminoadenosine, 5'-N-methylcarboxamidoadenosine MECA, N⁶-phenethyladenosine, 2-p-(2-carboxyethyl)-phenethyl-amino-5'-N-ethylcarboxamido-adenosine, N-ethylcarboxamido-adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)-ethyl]adenosine DPMA, metrifudil, erythro-9-(2-hydroxy-3-nonyl) adenine, iodotubercidin, salts of adenosine and esters of adenosine.

20. (Currently Amended): The method of Claim 10, wherein said composition further comprises at least one adenosine compound selected from the group consisting of an agonist of an adenosine receptor, a compound which increases intra- or extra-cellular adenosine levels, 2'-deoxyadenosine, 2',3'-isopropoylidene adenosine, toyocamycin, 1-methyladenosine, N-6-methyladenosine, adenosine N-oxide, 6-methylmercaptapurine riboside, 6-chloropurine riboside, 5'-adenosine monophosphate, 5'-adenosine diphosphate, 5'-adenosine triphosphate, phenylisopropyl adenosine, 1-methylisoguanosine, N⁶-cyclohexyl adenosine, N⁶-cyclopentyl adenosine, 2-chloro-N-6-cyclopentyladenosine, 2-chloroadenosine,

N⁶-phenyladenosine, 2-phenylaminoadenosine, 5'-N-methylcarboxamidoadenosine MECA, N⁶-phenethyladenosine, 2-p-(2-carboxyethyl)-phenethyl-amino-5'-N-ethylcarboxamido-adenosine, N-ethylcarboxamido-adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)-ethyl]adenosine DPMA, metrifudil, erythro-9-(2-hydroxy-3-nonyl) adenine, iodotubercidin, salts of adenosine and esters of adenosine.

21. (Previously Presented): The method of claim 1, comprising topically applying to the skin an effective amount of said composition to reduce laugh lines and/or reduce frown lines.

22-23. (Canceled).

24. (Previously Presented) The method of claim 19, wherein the composition further comprises at least one adenosine compound selected from the group consisting of an agonist of an adenosine receptor and a compound which increases intra- or extra-cellular adenosine levels.

25. (Previously Presented) The method of claim 19, wherein the composition further comprises at least one adenosine compound selected from the group consisting of: 2'-deoxyadenosine; 2',3'-isopropoylidene adenosine; toyocamycin; 1-methyladenosine, N-6-methyladenosine; adenosine N-oxide; 6-methylmercaptapurine riboside; 6-chloropurine riboside; 5'-adenosine monophosphate; 5'-adenosine diphosphate and 5'-adenosine triphosphate.

26. (Currently Amended): The method of claim 19, wherein the composition further comprises at least one adenosine compound selected from the group consisting of phenylisopropyl adenosine, 1-methylisoguanosine, N⁶-cyclohexyl adenosine, N⁶-cyclopentyl

adenosine, 2-chloro-N-6-cyclopentyladenosine, 2-chloroadenosine, N⁶-phenyladenosine, 2-phenylaminoadenosine, 5'-N-methylcarboxamidoadenosine ~~MECA~~, N⁶-phenethyladenosine, 2-p-(2-carboxyethyl)-phenethyl-amino-5'-N-ethylcarboxamido-adenosine, N-ethylcarboxamido-adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)-ethyl]adenosine ~~DPMA~~ and metrifudil.

27. (Previously Presented) The method of claim 19, wherein the composition further comprises at least one adenosine compound selected from the group consisting of erythro-9-(2-hydroxy-3-nonyl) adenine and iodotubercidin.

28. (Currently Amended) The method of claim 19, wherein the composition further comprises at least one ester ~~adenosine compound selected from the group consisting of~~ ~~adenosine and esters~~ of adenosine.

29. (Previously Presented): The method according to Claim 1, comprising topically applying to the skin an amount of said composition effective to provide a relaxing effect on dermal contractile cells associated with the expression lines, thereby softening the expression lines.

30. (Previously Presented): The method according to Claim 1, wherein the expression lines are at least one selected from the group consisting of crow's feet, nasogenic furrows, inter-eyebrow lines and forehead lines.

31. (Previously Presented): The method according to claim 29, wherein the composition comprises 0.1% to 1% by weight of adenosine with respect to the total composition weight.